Evidence map›Paper›PMID 40671796›Full record

ArticleResearch square2025

Identification of initial sites of SIV rebound after treatment cessation.

Louis Picker, Brandon Keele, Afam Okoye, Taina Immonen, Benjamin Varco-Merth, Derick Duell, Candice Nkoy, William Goodwin, Shelby Hoffmeister, Emek Kose and 18 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Louis PickerOregon Health & Science University.
Brandon KeeleFrederick National Laboratory for Cancer Research.ORCID 0000-0002-2381-1151
Afam OkoyeOregon Health and Sciences University.
Taina ImmonenFrederick National Laboratory for Cancer Research.
Benjamin Varco-MerthOregon Health and Sciences University.
Derick DuellOregon Health and Sciences University.
Candice NkoyOregon Health and Sciences University.
William GoodwinOregon Health and Sciences University.
Shelby HoffmeisterOregon Health and Sciences University.
Emek KoseFrederick National Laboratory for Cancer Research.
Andrew ConchasFrederick National Laboratory for Cancer Research.
Charles GoodmanFrederick National Laboratory for Cancer Research.ORCID 0000-0002-7968-9466
Christine FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research.
Agatha MacairanFrederick National Laboratory for Cancer Research.
William BoscheFrederick National Laboratory, Leidos Biomedical Research, Inc.
Randy FastFrederick National Laboratory, Leidos Biomedical Research, Inc.ORCID 0000-0003-3042-9214
Christopher HomickFrederick National Laboratory for Cancer Research.
Michael HullFrederick National Laboratory.
Kelli OswaldSAIC Frederick, Inc.
Rebecca ShoemakerNational Cancer Institute.
Lorna SilipinoFrederick National Laboratory for Cancer Research.
Jorden WelkerFrederick National Laboratory for Cancer Research.ORCID 0000-0003-3507-5072
Jeremy SmedleyUniversity of Louisiana at Lafayette.ORCID 0000-0003-3369-4662
Caralyn LabriolaOregon Health and Sciences University.ORCID 0000-0002-8271-6242
Michael AxthelmOregon Health & Science University.ORCID 0000-0002-1984-5906
Jacob EstesOregon Health & Science University.
Dan BarouchBeth Israel Deaconess Medical Center.ORCID 0000-0001-5127-4659
Jeffrey LifsonSAIC Frederick, Inc., NCI Frederick.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
NIAID NIH HHS UM1 AI164560NIH HHS P51 OD011092
6 · The paper itself

Abstract

Antiretroviral therapy (ART) suspends HIV replication, but virus persists and rebounds after ART discontinuation. Although much is known about the persistent viral population, the tissue origin(s) and the earliest viral dynamics of post-ART viral rebound remain obscure. Here, using barcoded SIVmac239 in rhesus macaques (RMs) and extensive necropsy tissue sampling on ART and early post ART, we defined the spectrum of low-level barcode-specific viral RNA expression in tissues during ART and then assessed initial clonal rebound by identifying barcodes in individual tissues that exceeded this distribution limit ("outliers"). Eight such outlier barcodes were identified in 4 of 11 aviremic (<1 copy/mL) post-ART RM, with 16 additional outliers in 5 of 6 post-ART RM with low viremia (5-30 copies/ml). Nine of these 16 barcodes were also identified in rebound viremia, confirming specific tissues as rebound origin sites. An RM with post-ART viremia of 4700 copies/mL showed 8 outlier barcodes that ranged from a single site to anatomically discontinuous, multi-site spread. Among all identified outlier barcodes, 27 were determined to reflect rebound origins, of which 96% were in the gastrointestinal (GI) tract (26%) or GI-tract-draining lymphoid tissues (70%). These results indicate that distinct tissue sites differentially restrict/promote post-ART viral rebound, with potential therapeutic implications for interventions designed to prevent or control these events.

Identifiers

PMID40671796
PMCPMC12265169

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.